A combination of toripalimab and perioperative chemotherapy significantly extended EFS compared with chemotherapy alone among patients with resectable stage III non-small cell lung cancer, according to results of a randomized phase 3 study.The findings of the Neotorch study, presented during an ASCO Plenary Series session, also showed the addition of toripalimab (Junshi Biosciences) to